Friday, October 30, 2026
Via News Knowledge File

Anthropic

organization80% conf.·synced Oct 29, 2026

AI company developing Claude AI assistant

58
sourced metrics
1914
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Fundraising Valuation
2trillion_USD
Revenue Run Rate
7billion_USD
Revenue
10billion_USD
Backlog
21USD
Projected Ipo Valuation
2000USD
Potential Ipo Valuation
60USD
New Customer Preference
73.3percent
Market Cap
380000000000USD
⚠ sources conflictsource
Prospectus Length
335pages
Oct 26, 2026source
Ipo Prospectus Length
335pages
Oct 26, 2026source
Ipo Valuation Target
2000USD
Oct 22, 2026source
Annualized Revenue Run Rate
67USD
Sep 30, 2026source
Acquisition Count
5acquisitions
Sep 29, 2026source
Infrastructure Commitments
518USD
Sep 29, 2026source
Noncancelable Commitments Share
80percent
Sep 29, 2026source
Cumulative Funding Raised
125USD
Sep 2, 2026source
Compute Capacity Secured
5gigawatts
Aug 31, 2026source
Acquisition Count This Year
5companies
Aug 24, 2026source

Stated objectives

Complete $50 billion US data center buildout

source
target: 50 billion USD stated

Prove that superior orchestration of existing models can yield exponential productivity gains as alternative to trillion-dollar infrastructure build-outs

source
stated

Halt training or delete model weights if safety and security standards cannot be met

source
stated

Target users running Claude Code continuously in the background 24/7 with new rate limits

source
target: less than 5 percent of users affected stated

Race to develop expert-level and superhuman AI systems

source
stated

Expand Cowork beyond macOS to Windows and add cross-device sync, growing access beyond Claude Max subscribers

source
stated

Make working with Claude feel less like operating a tool and more like delegating to a colleague, targeting mainstream non-technical users

source
stated

Continue developing agent safety mechanisms including defenses against prompt injection attacks as an active area of development

source
stated

Anthropic reportedly targeting its own IPO

source
stated

Diversify compute supply beyond Nvidia by expanding use of Amazon Trainium and Google TPUs to reduce concentration risk and improve hardware availability

source
stated

Relationship graph · 1914 connections

Competes with
559
Developed by
482
Customer of
158
Invested in
141
Supplies to
123
Employs
119
regulates
63
Covered by
34

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com